At Biogen, we develop, market and manufacture therapies for people living with serious neurological, autoimmune and hematologic disorders.

from https://www.biogen.com/

Research Grants 29 show all


$23.7M
2013

$32.2M
2015

$20.9M
2016

$16M
2017

$382.3K
2018

Publications 920 show all

  • 21
    Multiple Sclerosis, Relapsing-Remitting/drug therapy
  • 16
    Proteins/chemistry
  • 14
    Protein Engineering/methods
  • 14
    Receptors, Tumor Necrosis Factor/metabolism
  • 13
    Antibodies, Monoclonal/chemistry
  • 12
    Drug Design
  • 12
    Tumor Necrosis Factors/metabolism
  • 11
    Antibodies, Monoclonal, Humanized/therapeutic use
  • 11
    Antibodies, Monoclonal/therapeutic use
  • 11
    Multiple Sclerosis/drug therapy

Patents 7,288show all

  • 2,827
    A61K - Preparations for medical, dental, or toilet purposes
  • 2,641
    C07K - Peptides
  • 608
    C12N - Microorganisms or enzymes
  • 496
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 465
    C07D - Heterocyclic compounds
  • 267
    Y02A - Technologies for adaptation to climate change
  • 177
    A01K - Animal husbandry
  • 146
    C07C - Acyclic or carbocyclic compounds
  • 134
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 117
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture

Clinical Trials 661show all

270N/A187Phase 3121Phase 236Phase 438Other

SEC Filings show all


216
8-K

73
10-Q

22
10-K

Contact Information

Cambridge, MA
United States